<DOC>
	<DOCNO>NCT02542267</DOCNO>
	<brief_summary>The objective ISR 14-04 study evaluate post-market safety effectiveness GORE® VIABAHN® Endoprosthesis treatment In-Stent Restenosis Superficial Femoral Artery .</brief_summary>
	<brief_title>In-Stent Restenosis Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Patient previously implant ( &gt; 30 day ) noncovered stent ( ) locate SFA Patient lifestyle limit claudication , rest leg pain minor tissue loss ( Rutherford Category 2 5 ) Patient demonstrate Ankle Brachial Index ( ABI ) &lt; =0.9 . If ABI &gt; 0.9 measurable , patient eligible study Toe Brachial Index &lt; =0.5 Patient &gt; =50 % instent restenosis / occlusion previously implant ( &gt; 30 day ) noncovered stent ( ) locate superficial femoral artery define begin least 1cm origin profunda femoris artery end least 1cm intercondylar notch . Patient maximum total lesion length 270mm , consist instent adjacent occlusive disease Patient reference vessel diameter 4.0 6.5mm Patient least one patent infrapopliteal runoff vessel ( &lt; 50 % stenosis ) require reintervention Note : Additional Inclusion Criteria may apply Patient know allergy stent graft component ( nickeltitanium expandedpolytetrafluoroethylene ) Patient know intolerance anticoagulation antiplatelet therapy Patient know coagulation disorder , include hypercoagulability . Patient major distal amputation ( transmetatarsal ) Patient previous surgery target vessel Patient previous target vessel instent restenosis treat reline another stent Patient untreated flowlimiting aortoiliac stenotic disease Note : Additional Exclusion Criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bare Metal Stent</keyword>
	<keyword>In-Stent Restenosis</keyword>
</DOC>